Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome

Genes Chromosomes and Cancer

Volumn 50, Issue 7, 2011, Pages 535-545

  Sugawara, Waka ^a,b   Arai, Yasuhito ^c   Kasai, Fumio ^a   Fujiwara, Yuiko ^a   Haruta, Masayuki ^a   Hosaka, Rie ^a   Nishida, Kazunori ^a   Kurosumi, Masashi ^a   Kobayashi, Yasuhito ^a   Akagi, Kiwamu ^a   Kaneko, Yasuhiko ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGENASE 3; CYCLOPHOSPHAMIDE; DACTINOMYCIN; MYC PROTEIN; ONCOPROTEIN; PROTEIN BIRC2; PROTEIN BIRC3; PROTEIN DEPDC6; PROTEIN MAP3K1; PROTEIN P53; PROTEIN PVT1; PROTEIN TRIB1; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AMPLICON; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CARCINOGENESIS; CASE REPORT; CHILD; DRUG MEGADOSE; EMBRYONAL RHABDOMYOSARCOMA; FAMILIAL CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

ADULT; GENE AMPLIFICATION; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; INFANT; LI-FRAUMENI SYNDROME; MALE; MUTATION, MISSENSE; NEOPLASMS; ONCOGENES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79955664270     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20878     Document Type: Article

References (35)

1. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. 1999. Heterozygous germ line hCHK2 Mutations in Li-Fraumeni syndrome. Science 286: 2528-2531.
2. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X. 2006. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 38: 1133-1141.
3. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL. 2004. The combination of p53 mutation and neu/erbB2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 22: 86-96.
4. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S. 2008. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974.
5. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. 2001. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 19: 3091-3102.
6. Dai Z, Zhu W-G, Morrison CD, Brena RM, Smiraglia DJ, Raval A, Wu Y-Z, Rush LJ, Ross P, Molina JR, Otterson GA, Plass C. 2003. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet 12: 791-801.
7. Eeles RA. 1995. Germline mutations in the TP53 gene. Cancer Surv 25: 101-124.
8. Gibaud A, Vogt N, Hadj-Hamou N-S, Meyniel J-P, Hupe P, Debatisse M, Malfoy B. 2010. Extrachromosomal amplification mechanisms in a glioma with amplified sequences from multiple chromosome loci. Hum Mol Genet 19: 1276-1285.
9. Jin G, Yamazaki Y, Takuwa M, Takahara T, Kaneko K, Kuwata T, Miyata S, Nakamura T. 2007. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 109: 3998-4005.
10. Haruta M, Arai Y, Sugawara W, Watanabe N, Honda S, Ohshima J, Soejima H, Nakadate H, Okita H, Hata J, Fukuzawa M, Kaneko Y. 2008. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosomes Cancer 47: 712-727.
11. Hisada M, Garber JE, Fung CY, Fraumeni JF, Jr., Li FP. 1998. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90: 606-611.
12. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872.
13. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
14. Li FP, Fraumeni JF, Jr. 1969. Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome? Ann Intern Med 71: 747-752.
15. Ma O, Cai WW, Zender L, Dayaram T, Shen J, Herron AJ, Lowe SW, Man TK, Lau CC, Donehower LA. 2009. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res 69: 2559-2567.
16. Meek DW. 2009. Tumour suppression by p53: A role for the DNA damage response? Nat Rev Cancer 9: 714-723.
17. Mondello C, Smirnova A, Giulotto E. 2010. Gene amplification, radiation sensitivity and DNA double-strand breaks. Mutat Res 704: 29-37.
18. Nannya Y, Sanada S, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. 2005. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65: 6071-6079.
19. Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y, Oka Y, Tanizawa Y. 2003. MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF- kappa B activation. Oncogene 22: 7774-7780.
20. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860.
21. Oliver M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel CC, Hainaut P. 2009. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 16: 1-12.
22. Parham DM, Barr FG. 2002. Embryonal rhabdomyosarcomas. In: Fletcher CDM, Unni FK, Mertens F, editors. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, pp. 146-149.
23. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainau P, Oliver M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
24. Rieber J, Remke M, Hartmann C, Korshunov A, Burkhardt B, Sturm D, Mechtersheimer G, Wittmann A, Greil J, Blattmann C, Witt O, Behnisch W, Halatsch ME, Orakcioglu B, von Deimling A, Lichter P, Kulozik A, Pfister S. 2009. Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. Genes Chromosomes Cancer 48: 558-568.
25. Robles AI, Harris CC. 2010. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2: a001016.
26. Schneider K, Garber J. Li-Farumeni syndrome. 2010. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington.
27. Song H, Hollstein M, Xu Y. 2007. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9: 573-580.
28. Storlazzi CT, Fioretos T, Surace C, Lonoce A, Mastrorilli A, Strömbeck B, D'Addabbo P, Iacovelli F, Minervini C, Aventin A, Dastugue N, Fonatsch C, Hagemeijer A, Jotterand M, Mühlematter D, Lafage-Pochitaloff M, Nguyen-Khac F, Schoch C, Slovak ML, Smith A, Solè F, Van Roy N, Johansson B, Rocchi M. 2006. MYC-containing double minutes in hematologic malignancies: Evidence in favor of the episome model and exclusion of MYC as the target gene. Hum Mol Genet 15: 933-942.
29. Sung L, Anderson JR, Donaldson SS, Spunt SL, Crist WM, Pappo AS. 2004. Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group. Eur J Cancer 40: 1978-1885.
30. Tanaka H, Yao M-C. 2009. Palindromic gene amplification: An evolutionarily conserved role for DNA inverted repeats in the genome. Nat Rev Cancer 9: 215-224.
31. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaïti-Pellié C, Stoppa-Lyonnet D, Frébourg T. 2009. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27: e108-109.
32. Yokoyama T, Kanno Y, Yamazaki Y, Takahara T, Miyata S, Nakamura T. 2010. Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis. Blood 116: 2768-2775.
33. Vogt N, Lefevre S-H, Apiou F, Dutrillaux A-M, Cor A, Leuraud P, Poupon M-F, Dutrillaux B, Debatisse M, Malfoy B. 2004. Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc Natl Acad Sci 101: 11368-113737.
34. von Engelhardt J, Mack V, Sprengel R, Kavenstock N, Li KW, Stern-Bach Y, Smit AB, Seeburg PH, Monyer H. 2010. CKAMP44: A brain-specific protein attenuating short-term synaptic plasticity in the dentate gyrus. Science 327: 1518-1522.
35. Wahl GM. 1989. The importance of circular DNA in mammalian gene amplification. Cancer Res 49: 1333-1340.